







## OZON PHARMACEUTICALS GROUP

is the **leading** Russian pharmaceutical company, the main player in terms of sales of pharmaceuticals among local manufacturers, and No. 1 in scope of approved products portfolio. The company's products are presented in all pharmaceutical niches: traditional low-molecular pharmaceuticals, the production of drugs for the treatment of cancer and complex autoimmune diseases, as well as high-tech medicines in the field of biotechnology.

**The company is the absolute leader of production of generics in the country.**

- Ozon LLC
- Ozon Pharm LLC
- Mabscale LLC
- Ozon Medica LLC (under construction)

# COMPANY HISTORY

**2001** – A decision has been taken to create a company and build a production complex in Zhigulevsk.

**2002** – Construction of production complex for OZON pharmaceutical company has been completed.

**2003** – First batches of drugs were produced.

**2004** – Over 1 billion tablets and capsules have been produced. The company's portfolio includes 20 finished pharma products.

**2005** – OZON started to promote the first branded generic drug.

**2006** – The company's portfolio includes more than 30 finished pharma products. 4 branded generic drugs are registered. OZON drugs are registered in the CIS countries. Production volume is more than 60 million packs.

**2007** – Over 1.5 billion tablets and capsules have been Produced. The company's portfolio includes 36 finished pharma products.

**2008** – Construction of a warehouse complex has been completed. The production site has upgraded its equipment and increased production capacity.

**2009** – OZON entered the list of TOP 100 of pharmaceutical companies. Production volume exceeded 100 million packs.

**2010** – OZON is 13th in the ranking of Russian pharmaceutical manufacturers. A new warehouse complex has been launched. Construction of a new production complex is nearing completion.

**2012** – Production of soft forms has been launched. The first ointment was produced.

- 
- 2013** – OZON takes the 5th place in the influential ranking among local pharmaceutical companies. The company's portfolio includes more than 150 names of medicinal products.
- 2014** – European GMP certificate has been obtained. Production of sterile forms was launched. The first sterile solution was released.
- 2015** – A decision has been taken to build a new production complex in Tolyatti.
- 2017** – The second Ozon Pharm production complex was launched in Tolyatti.
- 2019** – OZON became the driver of the retail commercial market, taking a leading position in the ranking among companies that produce generics in Russia. Growth +50%. The company launched a global project of expansion into overseas markets.
- 2020** – The company registered its manufacturing sites in UAE, Iraq, Yemen, Cambodia. Drugs delivery to overseas markets has started.
- 2021** – The launch of Ozon Medika site construction for production of high toxic anti-cancer drugs.
- 2022** – The company's production sites were registered in the Philippines and Sri-Lanka.
- 2023** – Ozon LLC received its first Marketing Authorization for a medicinal drug in an overseas country, the UAE.
- 2024** – becoming as IPO PJSC «Ozon Pharmaceuticals», 3.5 billion ruble was raised for the implementation of a sustainable growth strategy.




For more than 20-year history, the company has been able to achieve a strong market position and consistently continues to perform one of the best revenue growth rates in the industry.

Ozon Pharmaceuticals PJSC (OZPH) shares are traded on the Moscow Exchange and are included in the broad market, consumer sector and Moscow Exchange IPO equity indices.



The manufacturing sites of the company comply with the measures of Good Manufacturing Practice for medicinal products and have EU GMP certificates. High-quality products, compliant with EU standards, are being produced there.



# MANUFACTURING SITES OVERVIEW

## Ozon



2003  
Start of  
production

43000 sq. m.  
Production  
area

378 mln packs  
Annual production  
capacity

## Ozon Pharm



2017  
Start of  
production

21000 sq. m.  
Production  
area

284 mln packs  
Annual production  
capacity

## Ozon Medica

*Under construction*



2027  
Start of  
sales

25000 sq. m.  
Production  
area

9 mln packs  
Planned Annual  
production capacity

## Mabscale



2027  
Start of  
production

35000 sq. m.  
Production  
area

5 mln packs  
Planned Annual  
production capacity



# MABSCALE

Mabscale LLC is a biotechnological company specializing in the development and production of drugs based on Monoclonal Antibodies and Recombinant proteins. It is a full-cycle production site, from API up to a finished product production





# PRODUCT PORTFOLIO

The company's product portfolio includes more than 500 MA and counts more than 800 SKU.

Flexible production capacities along with the wide range of drugs allow to the Group to quickly adapt to the market demand, rotating assortment in favor of the most demanded and marginal positions in the market.



# PHARMACOTHERAPEUTIC GROUPS

The range of products covers more than 45 pharmacotherapeutic groups:



Cardio Vascular



Anti-Cancer



Neurology



Anti Diabetic  
Cholesterol Lowering  
Agents



Antibiotics and  
Antibacterial



Anti Allergic



Analgesics



Antiviral



Gastro Intestinal  
Drug



Expectorants




Vitamin



Antidepressant  
Sedative

## As well:

Anti-Fungal, Antiplatelet, Erectile Dysfunction, Dermatology, Anti-Tubercular, Anti-HIV, Hepatoprotective, Phlebotonics, Vasoconstrictor, Sedative, Anticoagulant, Antiseptics, Gynecology, Anti-Parasitic, Gluco- corticoid Ointment, Immunosuppressant, Respiratory, Thyroid Preparation, Antidiarrheal, Pulmonology, Anesthesia, Anti Gout, Antimigraine, Coagulant, Joint Health, Urology, Hepatology, Laxative, Ophthalmology, Vasodilatory, Spasmolytic and others.



# RESEARCH AND DEVELOPMENT

The company undertakes research activities and develops new drugs.

>250 **generics** under development

>25 **biosimilars** under development





## QUALITY CONTROL

The company has its own modern laboratories where the quality of products is constantly monitored both in production process and during independent studies. Zero recalls for released drugs from the market. Company's quality monitoring system includes 430 people. Company is a resident of Tolyatti Special Economic Zone and Skolkovo "Biomed" cluster.

### QUALITY CONTROL

- conducting of input control
- conducting of intermediate control
- the quality control of finished pharmaceutical products

### PRODUCTION MONITORING

- stability study of finished products
- the control of production parameters and storage conditions

### VERIFICATION

- the verification of technological processes and methods of analysis, equipment qualification

### PHARMACOVIGILANCE

- the safety review of drugs in the process of their circulation



# WAREHOUSE COMPLEX

The company has its own modernly equipped warehouse complex, including facilities with special storage conditions ("cold zone").

All warehouse facilities maintain the necessary storage conditions for raw materials and finished products' safe storage and fully comply with GMP requirements.

69000 sq. m. of production and warehouse areas.

**~120 mln packs** – Potential for simultaneous storage of packages in warehouses.

Storage and delivery of finished products is carried out in a strict compliance with GDP requirements.





## CONTACT DETAILS

### **ALEXANDRA ISAEVA**

International Business Development Director  
(LATAM/SEA)

tel.: +7 931 361 56 78

e-mail: [isaeva@ozonpharm.ru](mailto:isaeva@ozonpharm.ru)

Website: [www.ozonpharm.ru](http://www.ozonpharm.ru)

### **IVAN PARCHEVSKY**

International Business Development Director

tel.: +375 29 635 52 40

e-mail: [parchevsky@ozonpharm.ru](mailto:parchevsky@ozonpharm.ru)

Website: [www.ozonpharm.ru](http://www.ozonpharm.ru)